|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization显示文摘AIM To evaluate the value of pre-treatment 18F-FDG PET/CT in patients with HCC following liver radioembolization.METHODS We identified 34 patients with HCC who underwent an FDG PET/CT scan prior to hepatic radioembolization at our institution between 2009 and 2013. Patients wereseen in clinic one month after radioembolization and then at 2-3 mo intervals. We assessed the influence of FDG tumor uptake on outcomes including local liver control(LLC), distant liver control(DLC), time to distant metastases(DM), progression free survival(PFS) and overall survival(OS).RESULTS The majority of patients were males(n = 25, 74%), and had Child Pugh Class A(n = 31, 91%), with a median age of 68 years(46-84 years). FDG-avid disease was found in 19(56%) patients with SUVmax ranging from 3 to 20. Female patients were more likely to have an FDG-avid HCC(P = 0.02). Median follow up of patients following radioembolization was 12 months(1.2-62.8 mo). FDG-avid disease was associated with a decreased 1 year LLC, DLC, DM and PFS(P < 0.05). Using multivariate analysis, FDG avidity predicted for LLC, DLC, and PFS(all P < 0.05).CONCLUSION In this retrospective study, pre-treatment HCC FDGavidity was found to be associated with worse LLC, DLC, and PFS following radioembolization. Larger studies are needed to validate our initial findings to assess the role of F-18-FDG PET/CT scans as biomarker for patients with HCC following radioembolization. | Yazan Abuodeh Arash O Naghavi Kamran A Ahmed Puja S Venkat Youngchul Kim Bela Kis Junsung Choi Benjamin Biebel Jennifer Sweeney Daniel A Anaya Richard Kim Mokenge Malafa Jessica M Frakes Sarah E Hoffe Ghassan El-Haddad | 2016 | World Journal of Gastroenterology2016，22，47： | 3 |
| 2 | Personalized chemotherapy in clear cell adenocarcinoma of the urethra:A case report显示文摘BACKGROUND Clear cell adenocarcinoma of the urethra is a rare type of aggressive cancer with a poor prognosis.Clear cell carcinoma of the urethra represents less than 0.02%of all malignancies in women.Adenocarcinomas account for 10%of female urethral carcinomas,of which 40%are the clear cell variant.Determining the presence or absence of certain mutations through genetic testing may predict whether a patient with cancer may benefit from a particular chemotherapy regimen.CASE SUMMARY A 40-year-old woman presented with a 3-year history of slow urinary flow and a 3-mo history of urinary urgency and frequency as well as gross hematuria.An abdominal and pelvic computed tomography scan demonstrated enlarged lymph nodes in the abdomen and pelvis.A biopsy of a left inguinal lymph node microscopically confirmed a metastatic adenocarcinoma of the urethra.Specialized genetic testing determined personalized chemotherapy.She was treated successfully with a non-platinum-based chemotherapy consisting of paclitaxel and bevacizumab.Following 3 cycles of paclitaxel and bevacizumab,she attained significant clinical improvement,and response by FDG-Positron emission tomography(PET)imaging showed a definite improvement in size and metabolic activity.She achieved complete response after 6 cycles of therapy by PET scan.The patient concluded 11 cycles of paclitaxel and bevacizumab,and a subsequent PET scan confirmed progression of metastatic disease.The patient was then treated with two cycles of doxorubicin after which a PET scan revealed a mixed response to the treatment.CONCLUSION We report the first case of a patient with metastatic clear cell adenocarcinoma of the urethra who underwent personalized chemotherapy after testing for cancer gene alterations.Our unique case represents the safe and effective use of nonplatinum-based chemotherapy in clear cell adenocarcinoma of the urethra. | Lisa B E Shields Arash Rezazadeh Kalebasty | 2020 | World Journal of Clinical Oncology2020，11，4： | 3 |
| 3 | Protein stabilization by specific binding of guanidinium to a functional arginine-binding surface on an SH3 domain显示文摘 | ARASH Zarrine-Afsar ANTHONY Mittermaier KAY Lewis E | 2006 | Protein Science2006，15，1： | 1 |
| 4 | Randomised controlled trial of sequential intravenous and oral azithromycin compared with intravenous ceftriaxone followed by cefixime both in combination with clarithromycin in hospitalized patients with community-acquired pneumonia显示文摘 | Arash E Abdolreza A Mohammad M | 2011 | Eur Respir2011，38，： | 1 |
| 5 | The effect of pro- staglandin E2 and calcium gluconate on orthodontic tooth movement and root resorption in rats 显示文摘 | Massoud S Behnam E Arash S S | 2003 | European Journal of Orthodontics2003，25，3： | 1 |
| 6 | Numerical modeling of multi- stranded hydraulic fracture propagation :accounting for the interac- tion between induced and natural fractures显示文摘 | Arash Dahi-Taleghani Jon E Oison | 2009 | SPE 1248842009，，： | 1 |
| 7 | Shake Table Response and Analysis of A Concrete-filled FRP Tube Bridge Column 显示文摘 | Arash E Zaghi Saiid Saiidi M Amir Mirmiran | 2012 | Composite Structures2012，94，： | 1 |
| 8 | Numerical modeling of multi- stranded-hydraulic fracture propagationt Accounting for the interaction between induced and natural fractures显示文摘 | ARASH D T OLSON J E | 2011 | SPE Journal2011，16，03： | 1 |
| 9 | Shake table studies of a concrete bridge pier utilizing pipe-pin two-way hinges显示文摘 | Arash E Zaghi Saiidi M Saiid Saad El-Azazy | 2011 | Journal of Bridge Engineering2011，16，5： | 1 |
| 10 | Modeling simultaneous growth of multiple hydraulic fractures and their interaction with natural fractures 显示文摘 | Olson J E Arash D T | 2009 | SPEl197392009，，： | 1 |
| 11 | Thromboembolic events in metastatic testicular cancer treated with cisplatin-based chemotherapy显示文摘BACKGROUND Testicular germ cell tumor(TGCT)is the most curable solid tumor and most common cancer among men 18-39 years.While cisplatin-based chemotherapy has significantly lengthened the survival of patients with TGCT,it is associated with a high rate of thromboembolic events(TEE).AIM To summarize our single-center experience highlighting patients who were diagnosed with TGCT and received platinum-based chemotherapy,with special attention to those patients who suffered a TEE.METHODS A retrospective analysis of the medical records and imaging studies of 68 consecutive individuals who were diagnosed with TGCT and received platinumbased chemotherapy at our Institution in a metropolitan community between January 1,2014 and December 31,2019.RESULTS A total of 19(28%)patients experienced a TEE following orchiectomy which occurred during chemotherapy in 13(68%)of these patients.Patients with a higher pathologic stage(stage III)were significantly(P=0.023)more likely to experience a TEE compared to patients who had a lower stage.Additionally,patients who were treated with 3 cycles of bleomycine,etoposide,and cisplatin and 1 cycle of etoposide and cisplatin or 4 cycles of etoposide and cisplatin were significantly 5(P=0.02)times more likely to experience a TEE compared to patients who were treated with only 3 cycles of bleomycine,etoposide,and cisplatin.CONCLUSION Due to numerous factors that predispose to a TEE such as large retroperitoneal disease,higher clinical stage,greater number of chemotherapy cycle,central venous catheter,cigarette smoking,and possible cannabis use,high-risk ambulatory patients with TGCT treated with cisplatin-based chemotherapy may benefit from prophylactic anticoagulation.Randomized studies to evaluate the safety and efficacy of prophylactic anticoagulants are warranted in this young patient population generally devoid of medical co-morbidities. | Lisa B E Shields Michael W Daniels Nataliya Mar Arash Rezazadeh Kalebasty | 2021 | World Journal of Clinical Oncology2021，12，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员